The
following potentially dilutive common stock equivalents outstanding at the period-end were excluded from the computation of diluted net
loss per share attributable to common stockholders for the periods indicated because including them would have had an anti-dilutive effect:
SCHEDULE OF ANTI-DILUTIVE SECURITIES EXCLUDED FROM COMPUTATION OF EARNINGS PER SHARE
| | |
Three Months Ended | | |
Three Months Ended | | |
Six Months Ended | | |
Six Months Ended | |
| | |
June 27, 2026 | | |
June 28, 2025 | | |
June 27, 2026 | | |
June 28, 2025 | |
| Nonvested restricted common stock | |
| 1,965,864 | | |
| 6,414,254 | | |
| 5,254,045 | | |
| 6,414,254 | |
| Stock options | |
| 734,726 | | |
| 591,366 | | |
| 1,316,004 | | |
| 591,366 | |
| Total | |
| 2,700,590 | | |
| 7,005,620 | | |
| 6,570,049 | | |
| 7,005,620 | |
|